Evaluation of antifungal pharmacodynamic characteristics of AmBisome against Candida albicans

Microbiology and Immunology

Volumn 50, Issue 8, 2006, Pages 579-586

  Takemoto, Koji ^a   Yamamoto, Yutaka ^a   Ueda, Yutaka ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Amphotericin B deoxycholate; Disseminated candidiasis; Liposomal amphotericin B; Time kill curve

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFECT; FUNGICIDAL ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TREATMENT OUTCOME;

CANDIDA ALBICANS; MURINAE;

EID: 33747828197     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2006.tb03832.x     Document Type: Article

References (23)

1. Adler-Moore, J., and Proffitt, R.T. 2002. AmBisome: liposomal formulation, structure, mechanism of action and preclinical experience. J. Antimicrob. Chemother. 49: 21-30.
2. Adler-Moore, J., and Proffitt, R.T. 2003. Effect of tissue penetration on AmBisome efficacy. Curr. Opin. Investig. Drugs 4: 179-185.
3. Andes, D., and Craig, W.A. 2003. Pharmacodynamics of the new des-F(6)-quinolone garenoxacin in a murine thigh infection model. Antimicrob. Agents Chemother. 47: 3935-3941.
4. Andes, D., Stamsted, T., and Conklin, R. 2001. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob. Agents Chemother. 45: 922-926.
5. Boswell, G.W., Buell, D., and Bekersky, I. 1998. AmBisome (liposomal amphotericin B): a comparative review. J. Clin. Pharmacol. 38: 583-592.
6. Fujii, G. 1996. Vesicles, p. 491-526. In Rosoff, M. (ed), Liposomal amphotericin B (AmBisome): realization of the drug delivery concept, Marcel Dekker, Inc., New York.
7. Gondal, J.A., Swartz, R.P., and Rahman, A. 1989. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob. Agents Chemother. 33: 1544-1548.
8. Groll, A.H., Piscitelli, S.C., and Walsh, T.J. 1998. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. Pharmacol. 44: 343-500.
9. Hupe, J.M., James, A.C., Girard, P., and Bullier, J. 2001. Response modulations by static texture surround in area V1 of the macaque monkey do not depend on feedback connections from V2. J. Neurophysiol. 85: 146-163.
10. Jessup, C., Reyes, G., Fothergill, A., McCarthy, D., Rinaldi, M., Messer, S., Pfaller, M., and Ghannoum, M. 2000. A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B: a multicenter study. J. Chemother. 12: 22-29.
11. Klepser, M.E., Wolfe, E.J., Jones, R.N., Nightingale, C.H., and Pfaller, M.A. 1997. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother. 41: 1392-1395.
12. Miyazaki, T., Kohno, S., Kaku, M., Koga, H., and Yamaguchi, K. 1990. Liposome-encapsulated amphotericin B in the treatment of experimental murine candidiasis. Tohoku J. Exp. Med. 161: 273-281.
13. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A, National Committee for Clinical Laboratory Standards, Wayne, Pa.
14. Ostrosky-Zeichner, L., Marr, K.A., Rex, J.H., and Cohen, S.H. 2003. Amphotericin B: time for a new "gold standard." Clin. Infect. Dis. 37: 415-425.
15. Rex, J.H., Walsh, T.J., Sobel, J.D., Filler, S.G., Pappas, P.G., Dismukes, W.E., and Edwards, J.E. 2000. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin. Infect. Dis. 30: 662-678.
16. Rogers, T., and Balish, E. 1976. Experimental Candida albicans infection in conventional mice and germfree rats. Infect. Immun. 14: 33-38.
17. Saag, M.S., Graybill, R.J., Larsen, R.A., Pappas, P.G., Perfect, J.R., Powderly, W.G., Sobel, J.D., and Dismukes, W.E. 2000. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. 30: 710-718.
18. Shirley, E. 1977. A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment. Biometrics 33: 386-389.
19. Steel, R.G.D. 1959. A multiple comparison rank sum test: treatments versus control. Biometrics 15: 560-572.
20. Stevens, D.A., Kan, V.L., Judson, M.A., Morrison, V.A., Dummer, S., Denning, D.W., Bennett, J.E., Walsh, T.J., Patterson, T.F., and Pankey, G.A. 2000. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin. Infect. Dis. 30: 696-709.
21. Takemoto, K., Yamamoto, Y., Ueda, Y., Sumita, Y., Yoshida, K., and Niki, Y. 2004. Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis. J. Antimicrob. Chemother. 53: 311-317.
22. Walsh, T.J., Goodman, J.L., Pappas, P., Bekersky, I., Buell, D.N., Roden, M., Barrett, J., and Anaissie, E.J. 2001. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother. 45: 3487-3496.
23. Williams, D.A. 1986. A note on Shirley's nonparametric test for comparing several dose levels with a zero-dose control. Biometrics 42: 183-186.